HUNTINGTON’S DISEASE

 

Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.                     (abst – 1981)

http://www.ncbi.nlm.nih.gov/pubmed/6273940

 

EFFECTS OF CANNABIDIOL IN HUNTINGTON’S DISEASE                 (abst – 1986)

http://www.druglibrary.org/schaffer/hemp/medical/hunting1.htm

 

Loss of cannabinoid receptors in the substantia nigra in Huntington’s disease.

 

 

 

 

 

 

 

 

(abst – 1993)               http://www.ncbi.nlm.nih.gov/pubmed/8255419

 

Cannabis in movement disorders.               (abst – 1999)

http://www.ncbi.nlm.nih.gov/pubmed/10627163

 

Cannabinoid Receptor Messenger Rna Levels Decrease in a Subset of Neurons of the Lateral Striatum, Cortex and Hippocampus of Transgenic Huntington’s Disease Mice. (abst – 2000)        http://www.ncbi.nlm.nih.gov/pubmed/10891614

 

Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease.      (abst – 2001)                                       http://www.ncbi.nlm.nih.gov/pubmed/11447320

 

Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease.                                                                  (abst – 2002)  http://www.ncbi.nlm.nih.gov/pubmed/11842443

 

Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington’s disease.                                             (abst – 2002)  http://www.ncbi.nlm.nih.gov/pubmed/12709298

 

Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease.                                                                (abst – 2003)  http://www.ncbi.nlm.nih.gov/pubmed/12603833

 

Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate.                                                                      (abst – 2003)  http://www.ncbi.nlm.nih.gov/pubmed/12858038

 

The endocannabinoid system and Huntington’s disease.              (abst – 2003)

http://www.ncbi.nlm.nih.gov/pubmed/14529364

 

Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington’s disease transgenic mice.                                                                   (full – 2004)  http://onlinelibrary.wiley.com/doi/10.1111/j.1432-1033.2004.04460.x/full

 

Delayed onset of Huntington’s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.                                       (abst – 2004)  http://www.ncbi.nlm.nih.gov/pubmed/14667455

 

Cannabinoid control of motor function at the basal ganglia.               (abst – 2005)

http://www.ncbi.nlm.nih.gov/pubmed/16596785

 

Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington’s disease mice.      (abst – 2005)                       http://www.ncbi.nlm.nih.gov/pubmed/15953496

 

Nabilone Could Treat Chorea and Irritability in Huntington’s Disease              (letter – 2006)

http://neuro.psychiatryonline.org/article.aspx?articleid=102920

 

 

 

 

 

 

 

 

 

UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington’s disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.                                                                                              (abst – 2006)  http://www.ncbi.nlm.nih.gov/pubmed/16006105

 

Cannabinoids and neuroprotection in motor-related disorders.              (abst – 2007)

http://www.ncbi.nlm.nih.gov/pubmed/18220777

 

Altered Lipid Metabolism in Brain Injury and Disorders                 (full – 2008)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2293298/?tool=pmcentrez

 

The endocannabinoid system in Huntington’s disease.                (abst – 2008)

http://www.ncbi.nlm.nih.gov/pubmed/18781982

 

The endocannabinoid pathway in Huntington’s disease: a comparison with other neurodegenerative diseases.                                                           (abst – 2008)     http://www.ncbi.nlm.nih.gov/pubmed/17276576

 

Role of CB2 receptors in neuroprotective effects of cannabinoids.                (abst – 2008)

http://www.ncbi.nlm.nih.gov/pubmed/18291574

 

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity (full – 2009)                                      http://brain.oxfordjournals.org/content/132/11/3152.long

 

Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington’s disease.                                                             (abst – 2009)  http://www.ncbi.nlm.nih.gov/pubmed/19524019

 

The endocannabinoid system as a target for the treatment of motor dysfunction. (abst – 2009)

http://www.ncbi.nlm.nih.gov/pubmed/19220290?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPa nel.Pubmed_RVDocSum&ordinalpos=54

 

A pilot study using nabilone for symptomatic treatment in Huntington’s disease. (abst – 2009)

http://www.unboundmedicine.com/medline/ebm/record/19845035/abstract/A_pilot_study_using_nabilone_   for_symptomatic_treatment_in_Huntington%27s_disease_

 

Cannabinoids and neurodegenerative diseases.                (abst – 2009)

http://www.ncbi.nlm.nih.gov/pubmed/19839933

 

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease.                                                            (abst – 2009)  http://www.ncbi.nlm.nih.gov/pubmed/19115380

 

Medical Marijuana and Huntington’s Disease                (news – 2009)

https://www.marijuanadoctors.com/content/ailments/view/143?ailment=huntington-s-disease

 

 

 

 

 

 

 

 

Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo         (full – 2010)                                http://jnm.snmjournals.org/cgi/content/full/51/9/1413

 

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.                                                            (full – 2010)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2848893/?tool=pubmed

 

Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington’s disease. (full – 2010)                          http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931573/?tool=pubmed

 

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data (link to PDF – 2010)                                               http://www.mdpi.com/1424-8247/3/8/2689

 

The endocannabinoid system in gp120-mediated insults and HIV-associated dementia. (abst – 2010)                                    http://www.ncbi.nlm.nih.gov/pubmed/20353779

 

Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice.                                                                             (abst – 2010)  http://www.unboundmedicine.com/medline/ebm/record/20600638/abstract/Behavioural_and_molecular_co nsequences_of_chronic_cannabinoid_treatment_in_Huntington%27s_disease_transgenic_mice_

 

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                                  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

 

Prospects for cannabinoid therapies in basal ganglia disorders.              (full – 2011)

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165947/

 

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease.   (full – 2011)                            http://brain.oxfordjournals.org/content/134/1/119.long

 

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease.                                                    (abst – 2011)       http://www.ncbi.nlm.nih.gov/pubmed/21674569

 

Worsening of Huntington disease phenotype in CB1 receptor knockout mice. (abst – 2011)

http://www.unboundmedicine.com/medline/ebm/record/21406230/abstract/Worsening_of_Huntington_dise  ase_phenotype_in_CB1_receptor_knockout_mice_

 

Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease                                                  (abst – 2011)  http://www.unboundmedicine.com/medline/ebm/record/21459091/abstract/Metabolic_and_Type_1_cannab  inoid_receptor_imaging_of_a_transgenic_rat_model_in_the_early_phase_of_Huntington_disease_

 

Unbalance of CB1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington’s disease.                                                          (abst – 2011)  http://www.ncbi.nlm.nih.gov/pubmed/22207189

 

Cannabinoid modulation of neuroinflammatory disorders.             (full – 2012)

 

 

 

 

 

 

 

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386505/

 

The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription (full – 2012)                                            http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02175.x/full

 

Review article: The endocannabinoid system in normal and pathological brain ageing (abst – 2012)                                                   http://www.ncbi.nlm.nih.gov/pubmed/23108550

 

Cannabinoids: Novel Medicines for the Treatment of Huntington’s Disease. (abst – 2012)                                         http://www.ncbi.nlm.nih.gov/pubmed/22280340

 

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?                                                    (abst – 2012)         http://www.ncbi.nlm.nih.gov/pubmed/22625422

 

Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington’s Disease: Role of CB(1) and CB(2) Receptors.        (abst – 2012)                                      http://www.ncbi.nlm.nih.gov/pubmed/22860209

 

Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington’s disease and mouse models.                                                               (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/23167744

 

Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington’s Disease.                                                          (abst – 2012)  http://www.ncbi.nlm.nih.gov/pubmed/23238740

 

Share a link for